Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 25;9(12):1396.
doi: 10.3390/vaccines9121396.

Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy

Tahseen H Nasti  1 , Christiane S Eberhardt  1   2   3   4
Affiliations
Review

Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy

Tahseen H Nasti et al. Vaccines (Basel). .

Abstract

The use of immune checkpoint inhibitors (ICI) has substantially increased the overall survival of cancer patients and has revolutionized the therapeutic situation in oncology. However, not all patients and cancer types respond to ICI, or become resistant over time. Combining ICIs with therapeutic cancer vaccines is a promising option as vaccination may help to overcome resistance to immunotherapies while immunotherapies may increase immune responses to the particular cancer vaccine by reinvigorating exhausted T cells. Thus, it would be possible to reprogram a response with appropriate vaccines, using a particular cancer antigen and a corresponding ICI. Target populations include currently untreatable cancer patients or those who receive treatment regimens with high risk of serious side effects. In addition, with the increased use of ICI in clinical practice, questions arise regarding safety and efficacy of administration of conventional vaccines, such as influenza or COVID-19 vaccines, during active ICI treatment. This review discusses the main principles of prophylactic and therapeutic cancer vaccines, the potential impact on combining therapeutic cancer vaccines with ICI, and briefly summarizes the current knowledge of safety and effectiveness of influenza and COVID-19 vaccines in ICI-treated patients.

Keywords: COVID vaccines; cancer vaccines; influenza; preventive vaccines; therapeutic vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Zhivaki D., Borriello F., Chow O.A., Doran B., Fleming I., Theisen D.J., Pallis P., Shalek A.K., Sokol C.L., Zanoni I., et al. Inflammasomes within Hyperactive Murine Dendritic Cells Stimulate Long-Lived T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2020;33:108381. doi: 10.1016/j.celrep.2020.108381. - DOI - PMC - PubMed
    1. Wieland A., Patel M.R., Cardenas M.A., Eberhardt C.S., Hudson W.H., Obeng R.C., Griffith C.C., Wang X., Chen Z.G., Kissick H.T., et al. Defining HPV-specific B cell responses in patients with head and neck cancer. Nature. 2020;597:274–278. doi: 10.1038/s41586-020-2931-3. - DOI - PMC - PubMed
    1. Kavanagh K., Pollock K.G., Cuschieri K., Palmer T., Cameron R.L., Watt C., Bhatia R., Moore C., Cubie H., Cruickshank M., et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: A 7-year cross-sectional study. Lancet. Infect. Dis. 2017;17:1293–1302. doi: 10.1016/S1473-3099(17)30468-1. - DOI - PubMed
    1. Saslow D., Andrews K.S., Manassaram-Baptiste D., Smith R.A., Fontham E.T.H. Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation. CA A Cancer J. Clin. 2020;70:274–280. doi: 10.3322/caac.21616. - DOI - PubMed
    1. Drolet M., Benard E., Perez N., Brisson M., Group H.P.V.V.I.S. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. Lancet. 2019;394:497–509. doi: 10.1016/S0140-6736(19)30298-3. - DOI - PMC - PubMed

LinkOut - more resources